Essential Premium

Biopharma’s Remarkable Reversal of Fortune

Life sciences and biopharma hedge funds have been on a tear for the past few months. Can it continue?

Valiant Tops Tiger Cubs as Hedge Funds Ride AI, Power, and Chips to Big Gains

Chris Hansen’s fund leads the pack with a 30.8 percent return, but Lone Pine, Discovery, Light Street, and others also posted strong September results.

Sponsored

Why the Commodities Boom Is Different This Time

Chris Hohn’s TCI Soars on Aerospace Bets, Extends Lead Over S&P With September Gain

The concentrated hedge fund widened its already impressive lead over the broader market as aerospace giants GE and Safran continued to fuel the fund’s standout year.

Related Content

Biopharma Hedge Funds Extend Gains

Steve Taub

Casdin Capital Leads a Strong Month for Biopharma Funds

Steve Taub

Biopharma Hedge Funds Are in a Tailspin

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram